http://orcid.org/0000-0002-0953-7838
Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Yu Shen, Qiurui Nie, Yibi Zhang, Qian Cao, Zhuo Hou & Lijun Xu. (2021) Treatment Strategies for Cryptogenic Stroke Patients with Patent Foramen Ovale: What Do We Choose?. Neuropsychiatric Disease and Treatment 17, pages 3205-3214.
Read now
Read now
Mohitosh Biswas, Most. Sumaiya Khatun Kali, Tapash Kumar Biswas & Baharudin Ibrahim. (2021) Risk of major adverse cardiovascular events of CYP2C19 loss-of-function genotype guided prasugrel/ticagrelor vs clopidogrel therapy for acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis. Platelets 32:5, pages 591-600.
Read now
Read now
Lukai Zheng, Chunsong Yang, Lingbao Xiang & Zilong Hao. (2019) Genotype-guided antiplatelet therapy compared with conventional therapy for patients with acute coronary syndromes: a systematic review and meta-analysis. Biomarkers 24:6, pages 517-523.
Read now
Read now
Articles from other publishers (34)
Hua Gao, Nan Yang, Libo Yang, Hui Wang, Guoshan Zhang, Xueping Ma & Ning Deng. (2023) Advances and Perspectives in methods for identifying high platelet reactivity. Heliyon 9:12, pages e22214.
Crossref
Crossref
Lauren N Goncalves, Veerle van Velze, Frederikus A Klok, Pim Gal, Rimke C Vos, Jaap F Hamming & Koen E A van der Bogt. (2023) High on-treatment platelet reactivity in peripheral arterial disease: A systematic review. Vascular.
Crossref
Crossref
L. Li & S. Luo. (2023) Analysis of CYP2C19 Gene Genotype in Patients with Acute Cerebral Infarction and Its Relationship with Disease Progression. Russian Journal of Genetics 59:10, pages 1092-1097.
Crossref
Crossref
Ziwei Xi, Yong Wang, Qianhong Lu, Hong Qiu, Yanan Gao, Ang Gao & Runlin Gao. (2023) Implementation of CYP2C19 genotyping and clinical outcomes following percutaneous coronary intervention in East Asian patients treated with oral P2Y12 inhibitors. Thrombosis Research 228, pages 85-93.
Crossref
Crossref
Musalitdin Abdullaev, B. Kantemirova, Elena Chernysheva & Aleksandra Romanova. (2023) COST-UTILITY ANALYSIS OF PERSONALIZED ANTIPLATELET THERAPY. ASTRAKHAN MEDICAL JOURNAL, pages 17-26.
Crossref
Crossref
Astuti Giantini, Ina S. Timan, Rahajuningsih Dharma, Renan Sukmawan, Rianto Setiabudy, Idrus Alwi, Alida R. Harahap, Erlin Listiyaningsih, Lia G. Partakusuma, Arif R. Tansir, Windy Sahar & Rakhmad Hidayat. (2023) The role of clopidogrel resistance-related genetic and epigenetic factors in major adverse cardiovascular events among patients with acute coronary syndrome after percutaneous coronary intervention. Frontiers in Cardiovascular Medicine 9.
Crossref
Crossref
Cameron D. Thomas, Alexis K. Williams, Craig R. Lee & Larisa H. Cavallari. (2023)
Pharmacogenetics of
P2Y
12
receptor inhibitors
. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 43:2, pages 158-175.
Crossref
Crossref
Yichuan Zhang, Jinbo Bai, Fu Kang, Wei Li, Zaixing Xiao, Yong Ma & Erqing Chai. (2023) A nomogram to predict the risk of bleeding after discharge from stent-assisted ruptured aneurysm embolization in a Chinese population. Neurosurgical Review 46:1.
Crossref
Crossref
Matteo CastrichiniJasmine A. Luzum & Naveen Pereira. (2023) Pharmacogenetics of Antiplatelet Therapy. Annual Review of Pharmacology and Toxicology 63:1, pages 211-229.
Crossref
Crossref
Jason R. Lewis. 2022. Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays. Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays
1
47
.
Samantha Medwid & Richard B. Kim. (2022) Implementation of pharmacogenomics: Where are we now?. British Journal of Clinical Pharmacology.
Crossref
Crossref
J Kranendonk, LH Willems, RJ. van der Vijver-Coppen, M. Coenen, E. Adang, R. Donders, CJ Zeebregts, VHM Deneer, MMPJ Reijnen, C Kramers & MC Warlé. (2022) CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease: study design of a randomized controlled trial (GENPAD). American Heart Journal 254, pages 141-148.
Crossref
Crossref
Craig R. Lee, Jasmine A. Luzum, Katrin Sangkuhl, Roseann S. Gammal, Marc S. Sabatine, Charles Michael Stein, David F. Kisor, Nita A. Limdi, Yee Ming Lee, Stuart A. Scott, Jean‐Sébastien Hulot, Dan M. Roden, Andrea Gaedigk, Kelly E. Caudle, Teri E. Klein, Julie A. Johnson & Alan R. Shuldiner. (2022)
Clinical Pharmacogenetics Implementation Consortium Guideline for
CYP2C19
Genotype and Clopidogrel Therapy: 2022 Update
. Clinical Pharmacology & Therapeutics 112:5, pages 959-967.
Crossref
Crossref
Anh B. Nguyen, Larisa H. Cavallari, Joseph S. Rossi, George A. Stouffer & Craig R. Lee. (2022) Evaluation of race and ethnicity disparities in outcome studies of CYP2C19 genotype-guided antiplatelet therapy. Frontiers in Cardiovascular Medicine 9.
Crossref
Crossref
Abdullah N. Alkattan, Nashwa M. Radwan, Nagla E. Mahmoud, Amjad F. Alfaleh, Amal H. Alfaifi & Khaled I. Alabdulkareem. (2022) The efficacy of clopidogrel in preventing recurrent cardiovascular events among Arab population carrying different CYP2C19 mutations: systematic review and meta-analysis. Egyptian Journal of Medical Human Genetics 23:1.
Crossref
Crossref
Ben Rowland, Jonathan A. Batty, George D. Dangas, Roxana Mehran & Vijay Kunadian. 2022. Interventional Cardiology. Interventional Cardiology
420
438
.
Danilo Vieira de Lara, Daniela Oliveira de Melo, Lucas Caetano Araújo Silva, Thuane Sales Gonçalves & Paulo Caleb Júnior Lima Santos. (2022) Pharmacogenetics of clopidogrel and warfarin in the treatment of cardiovascular diseases: an overview of reviews. Pharmacogenomics 23:7, pages 443-452.
Crossref
Crossref
Mohitosh Biswas, Chonlaphat Sukasem, Most Sumaiya Khatun Kali & Baharudin Ibrahim. (2022)
Effects of the
CYP2C19
LoF allele on major adverse cardiovascular events associated with clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis
. Pharmacogenomics 23:3, pages 207-220.
Crossref
Crossref
Chuanhui Xu & Khai Pang Leong. (2021) Pharmacogenomics and Rheumatological Practice. Journal of Clinical Rheumatology and Immunology 21:02, pages 58-69.
Crossref
Crossref
Mohitosh Biswas & Sumaiya Khatun Kali. (2021) Association of CYP2C19 Loss-of-Function Alleles with Major Adverse Cardiovascular Events of Clopidogrel in Stable Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention: Meta-analysis. Cardiovascular Drugs and Therapy 35:6, pages 1147-1159.
Crossref
Crossref
Hong Ting Shi, Yong Yuan Chen, Xiao Ying Li, Jian Hua Luo, Guang Hong Zhong, Jia Jia Hu, Min Zhang & Bo Rong Zhou. (2021) The Dynamic Effect of Non-CYP3A4-Metabolized and CYP3A4-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction. Frontiers in Pharmacology 12.
Crossref
Crossref
Mohitosh Biswas, Shawonur Rahaman, Tapash Kumar Biswas & Baharudin Ibrahim. (2021) Risk of major adverse cardiovascular events for concomitant use of clopidogrel and proton pump inhibitors in patients inheriting CYP2C19 loss-of-function alleles: meta-analysis. International Journal of Clinical Pharmacy 43:5, pages 1360-1369.
Crossref
Crossref
Mohitosh Biswas. (2020) Global distribution of CYP2C19 risk phenotypes affecting safety and effectiveness of medications. The Pharmacogenomics Journal 21:2, pages 190-199.
Crossref
Crossref
Yi Zhang, Xiu-Jin Shi, Wen-Xing Peng, Jia-Lun Han, Bai-Di Lin, Ru Zhang, Yun-Nan Zhang, Jia-Lin Yan, Juan-Juan Wei, Yi-Fan Wang, Su-Wei Chen, Nan Nan, Zhen-Wei Fang, Yong Zeng & Yang Lin. (2021) Impact of Implementing CYP2C19 Genotype-Guided Antiplatelet Therapy on P2Y12 Inhibitor Selection and Clinical Outcomes in Acute Coronary Syndrome Patients After Percutaneous Coronary Intervention: A Real-World Study in China. Frontiers in Pharmacology 11.
Crossref
Crossref
Amitava Dasgupta & Amer Wahed. 2021. Clinical Chemistry, Immunology and Laboratory Quality Control. Clinical Chemistry, Immunology and Laboratory Quality Control
421
431
.
Ying-Ying Zheng, Ting-Ting Wu, Yi Yang, Xian-Geng Hou, Ying Gao, You Chen, Yi-Ning Yang, Xiao-Mei Li, Xiang Ma, Yi-Tong Ma & Xiang Xie. (2020) Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing percutaneous coronary intervention: a randomized controlled clinical trial. European Heart Journal - Cardiovascular Pharmacotherapy 6:4, pages 211-221.
Crossref
Crossref
Jean-Sébastien Hulot & Gilles Montalescot. (2020) Reply. JACC: Cardiovascular Interventions 13:12, pages 1495-1496.
Crossref
Crossref
Cheng-An Wang, Yi-Chen Hsieh, Chun-Yao Huang, Ju-Chi Liu, Ming-Hsiung Hsieh, Yung-Kuo Lin & Jong-Shiuan Yeh. (2020) Comparison between ticagrelor versus clopidogrel in long term outcomes of Taiwanese diabetic subjects with acute coronary syndrome undergoing successful revascularization. Medicine 99:19, pages e19969.
Crossref
Crossref
Ziwei Xi, Yujie Zhou, Yingxin Zhao, Xiaoli Liu, Jing Liang, Meng Chai, Ying Yu & Wei Liu. (2020) Ticagrelor Versus Clopidogrel in Patients with Two CYP2C19 Loss-of-Function Alleles Undergoing Percutaneous Coronary Intervention. Cardiovascular Drugs and Therapy 34:2, pages 179-188.
Crossref
Crossref
Junichiro Shimamatsu, Ken-ichiro Sasaki, Yoshio Katsuki, Tomohiro Kawasaki, Yoshinobu Murasato, Hidehiko Ajisaka, Hiroyoshi Yokoi, Hideki Tashiro, Atsushi Harada, Yuji Hirakawa, Yuta Ishizaki, Takashi Ishimatsu, Kotaro Kagiyama, Yoshihiro Fukumoto, Tatsuyuki Kakuma & Takafumi Ueno. (2019) Prasugrel effectively reduces the platelet reactivity units in patients with genetically metabolic dysfunction of cytochrome P450 2C19 who are treated with long-term dual antiplatelet therapy after undergoing drug-eluting stent implantation. Heart and Vessels 35:3, pages 312-322.
Crossref
Crossref
Daisuke Kitano, Tadateru Takayama, Daisuke Fukamachi, Suguru Migita, Tomoyuki Morikawa, Takehiro Tamaki, Keisuke Kojima, Takashi Mineki, Nobuhiro Murata, Naotaka Akutsu, Mitsumasa Sudo, Takafumi Hiro, Atsushi Hirayama & Yasuo Okumura. (2019) Impact of low‐dose prasugrel on platelet reactivity and cardiac dysfunction in acute coronary syndrome patients requiring primary drug‐eluting stent implantation: A randomized comparative study. Catheterization and Cardiovascular Interventions 95:1.
Crossref
Crossref
Kai Tan, Zhexun Lian, Yan Shi, Xiaxia Wang, Haichu Yu, Mengwan Li, Jianhui Tian & Yiping Ge. (2019)
The effect of
CYP2C19
genotype-guided antiplatelet therapy on outcomes of selective percutaneous coronary intervention patients: an observational study
. Personalized Medicine 16:4, pages 301-312.
Crossref
Crossref
Xing‐yu Hong, Jie Lin & Wei‐wei Gu. (2018) Risk factors and therapies in vascular diseases: An umbrella review of updated systematic reviews and meta‐analyses. Journal of Cellular Physiology 234:6, pages 8221-8232.
Crossref
Crossref
Troy J. Smith, Jessica L. Johnson, Abiy Habtewold & Melissa A. Burmeister. (2019) Cardiovascular Risk Reduction. Critical Care Nursing Clinics of North America 31:1, pages 15-30.
Crossref
Crossref